Premium
Benefits and drawbacks of moving to biosimilar medicines
Author(s) -
Houlton Sarah
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1773
Subject(s) - biosimilar , medicine , adalimumab , monoclonal antibody , intensive care medicine , risk analysis (engineering) , pharmacology , tumor necrosis factor alpha , immunology , antibody
The recent introduction of four biosimilars to the anti‐TNF monoclonal antibody adalimumab has raised the prospect of significant cost savings for the NHS. But what are biosimilar medicines, how easy is it to switch patients and how likely is it that large savings will be possible?